Why is the ATE price intentionally being kept low?Why is this happening?
I've been watching daily since 2014 and this is a well-known pattern. Look at where ATE.V IPO'd at and the current market cap based on a transaction 6 months ago where risk over time was NOT adjusted by the crooks at Echelon. Echelon took ATE.V public. Why did they not properly value Antibe? Because they are clearly a beneficiary and they cashed in AGAIN at $0.40. This is manipulation and one day, Echelon will pay the price.
With regards to the news today, certainly incredible reciprocal interest from Don Haut to be able to sell to Bayer another product at comparable numbers as his most recent transaction in October. Although speculative until proven otherswise, it appears the cards are being laid down on the road to a $1-2B partnership coming soon where time is the only variable and it has Bayer's name all over it. I hate Echelon even more when I think about this.
Bayer knows Antibe Therapeutics pipeline is the death of current NSAIDS. They need to have their hand in Antibe because if it goes to a competitor, this will be very bad, downside is much worse than even the $50B plus upside. We are not talking about one medication being disrupted, we are talking about entire families of medications being replaced once we learn more about Antibe Holdings and their plans with hydrogen sulfide based on the work of the world leader in the field, Dr. John Wallace of Antibe. As I've said before, it's quite possible Dr. Wallace is awarded a nobel for this work in medicine as the years go by, mainstream clearly has not caught on yet. As I've said before, somebody please slap this man with an award and get him on TV!
I believe it is only a matter of time. This first product, entire pipeline, patent rights, team, proven high-quality clinical trial results, and now Don Haut (direct path to Bayer) are far too impressive to ignore.
So why is the ATE price being intentionally kept low? What's the possibility it's to make the likelihood of a transaction higher to preserve the upside for their Big Pharma partner? Everyone win's situation. Now that Bayer's name by way of Don Haut is tied to ATE, I believe it will draw interest from other Big Pharma's. It is in any competitors interest to drive the purchase price up with any stategies and tactics with just rumors alone to impact Bayer.
Today is an amazing day based on what I can see. My guess is keep the price low for Bayer who's coming in real soon, so they can decide the best mutually beneficial long-term plan including transactional price.
One morning in 2021, there will be an email in your inbox from Antibe Therapeutics announcing partnership at new valuation, and once trading resumes the share price should be 10x (Bayer's not transacting at $600M CAD, there's going to be a lift to $1-2B is my guess). And we're just starting folks...
Bayer officially has indirect ties to Antibe! Let the rumors begin...
GLTA